Sibel Health Sensor Enters FDA Drug Development Tool Qualification Program

According to a recent LinkedIn post from Sibel Health, the company’s Aria cough monitoring sensor has been accepted into the FDA Drug Development Tool Clinical Outcome Assessment Qualification Program. The post describes this as the company’s third acceptance into the FDA DDT COA framework and links the milestone to the need for continuous and automated measures in respiratory health.

The LinkedIn post highlights that Aria is designed to provide real time, objective cough detection without capturing identifiable audio, which is framed as reducing burden for patients and researchers and addressing privacy concerns. For investors, progress within the FDA’s DDT COA pathway may signal increasing regulatory engagement and potential relevance of Sibel’s technology in clinical trials, which could strengthen its positioning with pharma partners and in the broader digital health and respiratory monitoring markets.

The post further suggests that Sibel Health aims to advance toward later qualification stages in the program, positioning Aria as a tool that could support drug development and patient care in chronic refractory cough. If the technology gains wider adoption in clinical trials, it could enhance Sibel Health’s recurring revenue opportunities from research partnerships and potentially differentiate the company in the competitive wearable and clinical outcome assessment technology space.